Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals has successfully completed its acquisition of Chimerix, Inc., a move that strengthens its late-stage oncology pipeline with the inclusion of dordaviprone, a promising treatment for H3 K27M-mutant diffuse glioma. This acquisition, valued at approximately $935 million in cash, sees Chimerix become a wholly-owned subsidiary of Jazz. Dordaviprone is under Priority Review by the FDA, with a potential commercial launch expected in the second half of 2025, pending approval. This acquisition not only adds a novel medicine to Jazz's portfolio but also underscores its commitment to addressing rare diseases. The transaction involved a tender offer of $8.55 per share for Chimerix's outstanding stock, concluded through the merger of Pinetree Acquisition Sub, Inc. with Chimerix. The process aims to leverage Jazz's development and commercial capabilities, extending dordaviprone's use in first-line settings following FDA's evaluation. Jazz Pharmaceuticals, headquartered in Dublin, continues to focus on life-changing medicines across its diverse therapeutic portfolio, guided by a patient-focused approach.